Physician profile
John C Tapp
NPI 1194799676
$25,100.61
in general payments reported to CMS, 2019-2025
60 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,278 · 2020: $12K · 2021: $2,921 · 2022: $1,871 · 2023: $1,965 · 2024: $1,630 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296 · Consulting Fee: $1,505 · Education: $79.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.15 |
| Consulting Fee | $1,505.00 |
| Education | $79.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,390.46 | 2019-2021 | |
| Pfizer INC. | $2,354.46 | 2019-2025 | |
| Abbvie INC. | $1,647.59 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $924.15 | 2019-2024 | Emgality, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $660.29 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $545.09 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $471.45 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $457.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $396.33 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $391.51 | 2020-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $373.21 | 2022 | |
| Merck Sharp & Dohme LLC | $369.38 | 2019-2023 | Verquvo, Belsomra |
| Amgen INC. | $336.11 | 2019-2025 | Otezla, Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $266.95 | 2020-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $262.41 | 2022-2025 | Auvelity |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.